Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Dec 30;43(2):103371. doi: 10.1016/j.amjoto.2021.103371

Risk factors for palatal and orbital involvement in mucormycosis epidemic–Report of a center in India

Vikram Kemmannu Bhat 1,, Kiran Ravindranath Bongale 1, Shriya Pramod Basti 1, Raveendra Parappa Gadag 1, Nikhila Kizhakkilottu 1, Eaiby Sebastian 1, Megha Kattayya Gopalegowda 1, Pavithra Thammaiah 1
PMCID: PMC9756424  PMID: 34995965

Abstract

Background

Mucormycosis of the nose and paranasal sinuses has emerged as an epidemic following COVID-19 pandemic. The management involves surgical debridement, the extent of which depends on the bulk of the disease. Extension to the orbit and palate depends on the involvement of specific sites in the nose and paranasal sinuses. This study intended to identify those sites.

Materials and methods

This was a single-center case-control study. There were 3 groups according to the region involved (Palate, orbit and both). The fourth group with neither involvement was the control. Scoring system was used to estimate the bulk of disease according to the site involved in MRI scan. Odds ratio and chi-square tests were used to study risk and association respectively. ROC curve was obtained for the MRI scores of the cases and controls.

Results

214 patients were studied in all; 44.39% and 61.68% had palate and orbit involvement, respectively. Maxillary sinus roof had significant association and the highest risk for spread of disease into the palate. The risk for the orbit to be involved was increased when there was disease in the cavernous and sphenoid sinus. For the orbit, the site with the significant association was the ethmoid sinus, infratemporal fossa and roof of the maxillary sinus.

Conclusion

Due attention should be given for clearance during surgical debridement to the high-risk sites to prevent recurrences and reduce morbidity and mortality. MRI scores were most helpful to identify the bulk of disease when both palate and orbit were involved.

Keywords: Mucormycosis, Palate, Orbit, Paranasal sinus, COVID-19

1. Introduction

Rhino-orbital Mucormycosis cases have emerged as an epidemic within the pandemic of COVID-19 in India and a few other nations. The majority of the patients have involvement of palate, orbit or both adding to the bulk of the disease thereby increasing the morbidity and mortality. The surgeries are extensive and mutilating when they are involved; hence there is a need to determine what leads to palatal or orbital extensions from the nose and paranasal sinuses so that these critical structures might be addressed better during debridement. It is difficult to predict the progressive course of the disease and the extent of involvement of the vital structures in the vicinity of the primary disease that might finally decide the fate of the patient. This spread directly affects the debridement clearance required in the patients.

This study intended to identify the involvement of critical structures that may lead to the extension of disease into the palate/upper alveolus and orbit from the nose and paranasal sinuses and also the patterns of disease presentations of Mucormycosis [MCM].

2. Materials and methods

This was a single center study undertaken for 3 months, in a tertiary referral public hospital during the peak of the epidemic of MCM in South India that commenced during the second wave of the COVID-19 pandemic. Clearance was obtained from the institutional ethics review board. Written informed consent was taken from all the patients. The study included patients of diabetes mellitus and COVID 19 history with and without orbital and or palatal involvement due to MCM of the nose and paranasal sinuses who had undergone surgical debridement for the same and also received Amphotericin B therapy.

The primary outcome was to identify the critical structures responsible for the involvement of the palate/alveolus, orbit or both [Regions]. The patterns of involvement of the various sites in the nose and the paranasal sinus [PNS] were also studied. This was a case-control study with 4 groups:

  • a.

    Case group A[A]: Nose, PNS and palate involved cases [stage 2]

  • b.

    Case group B [B]: Nose, PNS and orbit involved cases [stage 3]

  • c.

    Case group C [C]: Nose, PNS, palate and orbit involved cases [Stage 3] with CNS involvement [Stage 4]

  • d.

    Control group [D]: Nose, PNS or both involved cases [Stage 1]

Every consecutive eligible patient was included in the study. Adult patients in stages 1, 2, 3,4 of MCM of head and neck with diabetes mellitus and post COVID-19 infection (Based on magnetic resonance imaging [MRI], Diagnostic nasal endoscopy [DNE], biopsy and clinical findings) [1], [2]. Orbital involvement was confirmed by restriction of movement, loss or reduction of vision, chemosis, edema of eyelid, proptosis and redness of the eye. Palatal involvement was established by the presence of ulcer, swelling or loose tooth. Diabetes mellitus included precovid type 1, 2 or covid induced diabetes. Inoperable cases, chronic sinusitis without evidence of MCM or pre-existing diabetic retinopathy were excluded. A Scoring system to assess the bulk of disease for every patient was prepared according to the sites involved on the MRI and the net score was calculated [3]. The scoring pattern for the sites was as follows: middle/inferior turbinate, osteomeatal complex, nasal septum, cribriform plate, lateral wall of the maxillary cavity, infratemporal fossa, frontal sinus [Score 1], ethmoids, the floor of the nasal cavity, floor of the maxillary sinus, sphenoid sinus, roof of the maxillary sinus [score 2], pterygopalatine fossa, cavernous sinus [score 3]. The score of cases and controls was compared and analyzed.

2 ∗ 2 contingency tables were prepared separately for every suspected risk factor and the Odds ratio was calculated. Chi-square test was used for the study of the association at 95% confidence intervals. The sensitivity and specificity of the MRI scores in identifying the disease of group A, B, C was calculated. Standard error was calculated [95% confidence intervals] and the ROC curve was obtained by plotting sensitivity against 1-specificity. Stata version 21 was used for statistical analysis.

3. Results

Two hundred and fourteen patients were studied in all that included 170 males and 44 females. The youngest patient was aged 25 years and the oldest 80 years. The mean age was 50.29 ± 11.47. The distribution of the patients according to the age class interval is shown in Fig. 1 . The percentages of the patients in the individual groups and the admission discharge statistics are given in Table 1 . It was found that 44.39% of the patients had palatal involvement and 61.68% had orbital involvement. The most typical symptom and sign were craniofacial pain [Table 2 ] and nasal discharge [Table 3 ], respectively. The findings of the MRI done are given in Table 4 and the commonest site involved was the ethmoid sinus [Table 4]. The risk factor for each site was calculated by odds ratio and then the strength of the association with the palate and orbit [Table 5 ]. The MRI scores of the patients in the various groups is given in class intervals in Table 6 . The area under the ROC curves of groups A, B, C is shown in Fig. 2, Fig. 3, Fig. 4 , respectively. It was found that group C had the maximum area under ROC and hence the MRI scores were the most useful to identify the bulk of disease.

Fig. 1.

Fig. 1

Bar chart showing age class interval distribution in the four groups.

Table 1.

Admission discharge statistics of the patients in the 4 groups.

Status of patient A
B
C
D
Total
Palate Orbit Both None
Undergoing treatment 28 51 36 25 140 [65.42%]
Discharged from hospital on request 7 7 8 8 30
Discharge against medical advice 1 6 5 4 16
Expired 2 (5.26%) 11 (14.66%) 8 (14.03%) 7 (15.90%) 28 [13.08%]
Total 38 [17.75%] 75 [35.04%] 57 [26.63%] 44 [20.56%] 214

Table 2.

Symptoms in the 4 groups.

Symptoms A
B
C
D
Total
Palate Orbit Both None
Nasal obstruction 15 23 20 21 79 (36.91%)
Nasal discharge 13 14 12 11 50 (23.36%)
Craniofacial pain 27 54 36 27 144 (67.28%)
Blurred vision 0 22 11 6 39 (18.22%)
Eye swelling 7 55 41 5 108 (50.46%)
Fever 2 9 4 3 18 (8.41%)
Loose tooth/toothache 23 16 23 7 69 (32.24%)
Disorientation 0 1 2 0 3 (1.40%)
Vomiting 0 1 0 0 1 (0.46%)

Table 3.

Signs in the 4 groups.

Signs A
B
C
D
Total
Palate Orbit Both None
Nasal discharge 21 52 33 28 134 (62.61%)
Nasal eschar/slough 15 30 36 22 103 (48.13%)
Eyelid edema 3 57 37 4 101 (47.19%)
Eye congestion 1 27 23 0 51 (23.83%)
Diminished vision 0 26 15 0 41 (19.15%)
Restricted movements of eyeball 0 29 21 0 50 (23.36%)
Proptosis 0 21 15 0 36 (16.82%)
Palatal ulcer 30 0 41 0 71 (33.17%)
Loose or missing teeth 9 2 3 0 14 (6.54%)
Altered sensorium 0 0 6 0 6 (2.80%)

Table 4.

MRI findings suggesting the involvement of various sites in the craniofacial region.

MRI findings of involvement [sites] A
B
C
D
Total
Palate Orbit Both None
Middle turbinate 6 20 12 14 52 (24.29%)
Inferior turbinate 7 17 15 10 42 (19.62%)
Septum 2 0 4 0 6 (2.80%)
Lateral wall of maxillary sinus 18 40 26 22 106 (49.53%)
Roof of maxillary sinus 31 48 58 21 158 (73.83%)
Floor of maxillary sinus 33 48 32 25 138 (64.48%)
Floor of nasal cavity 3 5 3 1 12 (5.6%)
Ethmoid sinus 28 66 48 34 176 (82.24%)
Sphenoid sinus 22 56 42 21 141 (65.88%)
Frontal sinus 16 40 31 21 108 (50.46%)
Pterygopalatine fossa 4 7 8 3 22 (10.28%)
Infratemporal fossa 8 24 12 5 49 (22.89%)
Cavernous sinus 0 3 4 0 7 (3.27%)

Table 5.

The odds ratio and the strength of association found between the sites of the craniofacial region and the palate, orbit.

Site involved Palate
Palate
Orbit
Orbit
Odds ratio p-Value Odds ratio p-Value
Lateral wall of nasal cavity 0.39 0.001 1.63 0.09
Floor of the maxillary sinus 1.3 0.28 0.63 0.13
Roof of the maxillary sinus 10.74 <0.001 2.35 0.007
Lateral wall of maxillary sinus 0.79 0.41 1.05 0.86
Floor of nasal cavity/septum 2.72 0.05 1.26 0.67
Ethmoid sinus 0.76 0.45 2.04 0.05
Sphenoid sinus 1.12 0.69 2.61 0.001
Frontal sinus 0.93 0.80 1.41 0.22
Pterygopalatine fossa 1.57 0.32 1.37 0.50
Infratemporal fossa 0.82 0.57 1.99 0.05
Cavernous sinus 1.7 0.52 9.86 0.02

Table 6.

MRI scores of the patients in the 4 groups in class intervals.

MRI score A
B
C
D
Total
Palate Orbit Both None
1–3 3 2 0 7 12
4–6 9 15 7 14 45
7–9 14 29 26 19 88
10–12 8 21 18 3 50
13–15 4 4 5 1 14
16–18 0 4 1 0 5
Total cases 38 75 57 44 214

Fig. 2.

Fig. 2

Area under the ROC curve in palatal involvement only.

Fig. 3.

Fig. 3

Area under the ROC curve in orbital involvement only.

Fig. 4.

Fig. 4

Area under the ROC curve in both palatal and orbital involvement.

4. Discussion

In the past, several authors have studied a series of cases of MCM over the years [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]. Also, many cases of MCM have been reported recently (2021) across India and the rest of the world after the COVID-19 pandemic [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]. However, none has evaluated the risk factors for palatal and orbital involvement against a control. To the best of our knowledge, this is the first paper to assess and report the same. Just as the course of COVID-19 was unpredictable and could become serious in some, so was MCM in this study. Given the high morbidity and mortality of the disease, it is essential to identify the sites in and around the nose and the paranasal sinuses that get involved early and play a lead role in the further extension of the disease to vital organs. There were no apparent reasons or causes for the spread into the palate, orbit or the central nervous system in a few of them. The involvement of these regions additionally required the services of a maxillofacial surgeon, a prosthodontist, an oculoplastic surgeon and a neurosurgeon in our setup. Hence the number of surgeries that the patient had to undergo would increase, thereby increasing the duration of surgery and also the number of times the patient was subjected to general anesthesia.

Diagnosis is confirmed through biopsy and histological analysis of the affected tissues. On microscopy, broad-based ribbon-like non-septate hyphae with irregular right-angled branching are the key diagnostic microscopic features [32]. CT and MRI scans may suggest invasive MCM but they may often be nondiagnostic [11]. If angio-invasion is present, bone erosion may be absent even in the presence of progressive disease. Overall, CT and MRI may be most helpful in assisting surgical planning for, rather than the diagnosis of rhinocerebral MCM [11]. Periorbital cellulitis, extraocular muscle paresis, proptosis and chemosis frequently develop due to disease extension into orbit or cavernous sinus. Spread from the sphenoid sinuses to the adjacent cavernous sinus can result in cranial nerve palsies, thrombosis of the sinus and involvement of the carotid artery [33]. Multicompartmental and extra-sinonasal tissue infarction is possible without overt bone involvement and is caused by the propensity of fungal elements to disseminate from nasal cavity via the perineural and transvascular routes [10], [34], [35]. Angioinvasion with infarction and hematogenous spread are hallmarks of MCM [36], [37]. The fungal hyphae grow along the intimal elastic lamina leading to intimal hyperplasia and intravascular thrombosis, further leading to vessel occlusion [38], [39]. Most regions that proved to be a significant risk factor for either the palate or the orbit were the closely adjoining structures. However, paradoxically the roof of the maxillary sinus has been a high-risk factor for palatal involvement even though it was not the immediate adjacent structure. Besides, in many cases, it was observed during surgical debridement that there were hidden deep pockets of disease with apparently healthy bleeding tissues around them. This could have probably been possible by perineural spread via the infraorbital nerve [12]. A few authors have found the maxillary sinus to be the commonest sinus involved [2], [17], [29], [30]. However, Sharma S et al. found the maxillary sinus involvement only in 52.17% and ethmoid sinuses in 100% of the cases [18]. Likewise, the ethmoid was the commonest sinus involved and the palate was the commonest region in a study by Pippal SK et al. [22] and Kulkarni NS et al. [13]. Hosseini SMS et al. found the involvement of the pterygopalatine fossa in all 10 cases and concluded that it was the main reservoir acting as a conduit for other sites [12]. Mitra et al. [23] and Sen M et al. [25] also found orbit involvement in a more significant number of cases than palate, similar to our study. They opined that the angioinvasive nature and perineural spread were responsible for early optic nerve involvement and orbital apex syndrome. One of the routes of spread from the nasal cavity to the orbit is the nasolacrimal duct that can be noticed on CT soft tissue window [34]. The mortality in our study did not appear to be proportional to the bulk of the disease again, probably due to non-contiguous spread to the brain and cavernous sinus. COVID-19 related lung complications were yet another cause of mortality.

Extension of the disease into the maxillary and ethmoid sinus can lead to orbital involvement through the superior orbital fissure, ophthalmic vein and cribriform plate along the perivascular channels can occur intracranial spread [40]. As observed in Table 4, most of the spread to the orbit and palate depended on what got involved initially in the 3 main sites – ethmoid, the roof of the maxillary sinus and sphenoid sinus. Further, the involvement of other sites only added to the bulk of the disease and MRI score but probably did not play a role in the spread to the orbit and palate.

Even though the epidemic has slowed down considerably now, we still count. The present study could not continue until the end and depicts only a cross-section of the epidemic.

5. Conclusion

The disease in the roof of the maxillary sinus had a significant association and the highest risk to spread into the upper alveolus and the palate. The other sites with increased risk for palatal involvement were the floor of the nasal cavity and the pterygopalatine fossa. Similarly, the risk of involvement in orbit was highest when there was disease in the sphenoid sinus and the cavernous sinus. The other sites with significant association and high risk were the roof of the maxillary sinus, infratemporal fossa and ethmoid sinus. Due attention should be given to the clearance of disease in these high-risk sites during debridement surgery to prevent common recurrences and thus reduce morbidity and mortality. The contiguous spread was not always the rule and skip lesions were possible due to perineural and transvascular spread. MRI scores were most helpful to identify the bulk of disease when both the palate and orbit were involved and least beneficial when the palate alone was involved.

Acknowledgments

The authors wish to thank and acknowledge the support and the co-operation extended by the departments of ophthalmology, maxillofacial surgery, prosthodontics, pathology, microbiology, radiology, internal medicine and neurosurgery in patient care and the preparation of this paper.

References

  • 1.Honavar S.G. Rhino-orbito-cerebral mucormycosis- guidelines for diagnosis, staging and management. Indian J Ophthalmol. 2021;69:1361–1365. doi: 10.4103/ijo.IJO_1165_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sen M., Honavar S.G., Bansal R., Sengupta S., Rao R., Kim U., et al. Epidemiology, clinical profile, management and outcome of COVID-19 associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol. 2021;69:1670–1692. doi: 10.4103/ijo.IJO_1565_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Shah K., Dave V., Bradoo R., Shinde C., Prathibha M. Orbital exenteration in rhino-orbito-cerebral mucormycosis: a prospective analytical study with scoring system. Indian J Otolaryngol Head Neck Surg. 2019;71(2):259–265. doi: 10.1007/s12070-018-1293-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Balai E., Mummadi S., Jolly K., Darr A., Aldeerawi H. Rhinocerebral mucormycosis: a ten-year single centre case series. Cureus. 2020;12(11) doi: 10.7759/cureus.11776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kolekar J.S. Rhinocerebral mucormycosis: a retrospective study. Indian J Otolaryngol Head Neck Surg. 2015;67(1):93–96. doi: 10.1007/s12070-014-0804-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bakshi S.S., Das S., Ramesh S., Gopalakrishnan S. Nasal mucormycosis: our experience with 24 cases. Otolaryngol Pol. 2020;74(4):37–40. doi: 10.5604/01.3001.0013.8593. [DOI] [PubMed] [Google Scholar]
  • 7.Singh V.P., Bansal C., Kaintura M. Sinonasal mucormycosis: a to Z. Indian J Otolaryngol Head Neck Surg. 2019;71(Suppl 3):1962–1971. doi: 10.1007/s12070-018-1384-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rangel-Guerra R., Martínez H.R., Mucormycosis Sáenz C. Report of 11 cases. Arch Neurol. 1985;42(6):578–581. doi: 10.1001/archneur.1985.04060060080013. [DOI] [PubMed] [Google Scholar]
  • 9.Nussbaum E.S., Hall W.A. Rhinocerebral mucormycosis: changing patterns of disease. Surg Neurol. 1994;41(2):152–156. doi: 10.1016/0090-3019(94)90114-7. [DOI] [PubMed] [Google Scholar]
  • 10.Sravani T., Uppin S.G., Uppin M.S., Sundaram C. Rhinocerebral mucormycosis: pathology revisited with emphasis on perineural spread. Neurol India. 2014;62(4):383–386. doi: 10.4103/0028-3886.141252. [DOI] [PubMed] [Google Scholar]
  • 11.Ketenci I., Ünlü Y., Kaya H., Somdas M.A., Kontas O., Öztürk M., Vural A. Rhinocerebral mucormycosis: experience in 14 patients. J Laryngol Otol. 2011;125(8) doi: 10.1017/S0022215111000843. [DOI] [PubMed] [Google Scholar]
  • 12.Hosseini S.M., Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(11):932–938. doi: 10.1007/s00405-005-0919-0. [DOI] [PubMed] [Google Scholar]
  • 13.Kulkarni N.S., Bhide A.R., Wadia R.S. Rhinocerebral mucormycosis: an analysis of probable mode of spread and its implication in an early diagnosis and treatment. Indian J Otolaryngol Head Neck Surg. 2005;57(2):121–124. doi: 10.1007/BF02907665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jiang N., Zhao G., Yang S., Lin J., Hu L., Che C., et al. A retrospective analysis of eleven cases of invasive rhino-orbito-cerebral mucormycosis presented with orbital apex syndrome initially. BMC Ophthalmol. 2016;16:10. doi: 10.1186/s12886-016-0189-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Shakir M., Maan M.H.A., Waheed S. Mucormycosis in a patient with COVID-19 with uncontrolled diabetes. BMJ Case Rep. 2021;14(7) doi: 10.1136/bcr-2021-245343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Revannavar S.M., Samaga L., S.S. P., K.V. V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021;14(4) doi: 10.1136/bcr-2021-241663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chouhan M., Solanki B., Shakrawal N. Rhino-orbital-cerebral mucormycosis: fungal epidemic in a viral pandemic. J Laryngol Otol. 2021;135(11):981–986. doi: 10.1017/S0022215121002309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sharma S., Grover M., Bhargava S., Samdani S., Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135:442–447. doi: 10.1017/S0022215121000992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bal K.K., Alagoz S., Delibas V., Kuran G., Ozdas T., Yucel Ekici N. Did COVID-19 increase rhinoorbitocerebral mucormycosis?: 9 consecutive cases on pandemic days. B-ENT. 2021;17(3):149–154. doi: 10.5152/B-ENT.2021.20429. [DOI] [Google Scholar]
  • 20.Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12 doi: 10.7759/cureus.10726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021;7(4):298. doi: 10.3390/jof7040298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pippal S.K., Kumar D., Ukawat L. Management challenge of rhino-orbito-cerebral mucormycosis in covid 19 era: a prospective observational study. Indian J Otolaryngol Head Neck Surg. 2021:1–7. doi: 10.1007/s12070-021-02947-5. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mitra S., Janweja M., Sengupta A. Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control. Eur Arch Otorhinolaryngol. 2021:1–6. doi: 10.1007/s00405-021-07010-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Avatef Fazeli M., Rezaei L., Javadirad E., Iranfar K., Khosravi A., Amini Saman J., et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: an observational study. Mycoses. 2021;64:1366–1377. doi: 10.1111/myc.13351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sen M., Lahane S., Lahane T.P., Parekh R., Honavar S.G. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69:244–252. doi: 10.4103/ijo.IJO_297_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ravani S.A., Agrawal G.A., Leuva P.A., Modi P.H., Amin K.D. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69:1563–1568. doi: 10.4103/ijo.IJO_310_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dave T.V., Nair A.G., Hegde R., Vithalani N., Desai S., Adulkar N., et al. Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: a multi-centric study. Ophthalmic Plast Reconstr Surg. 2021;37(5):488–495. doi: 10.1097/IOP.0000000000002030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bayram N., Ozsaygılı C., Sav H., Tekin Y., Gundogan M., Pangal E., et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;65(4):515–525. doi: 10.1007/s10384-021-00845-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gupta S., Ahuja P. Risk factors for procurance of mucormycosis and its manifestations post covid-19: a single arm retrospective unicentric clinical study. Indian J Otolaryngol Head Neck Surg. 2021;(Sep 18):1–8. doi: 10.1007/s12070-021-02825-0. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Singhal A., Jain S., Sharma S., Kottiyath V.C., Khandelwal G. A multicentric observational study of imaging findings in COVID-19-related rhino-orbito-cerebral mucormycosis: a new pandora’s box. Egypt J Radiol Nucl Med. 2021;52:258. doi: 10.1186/s43055-021-00631-w. [DOI] [Google Scholar]
  • 31.Patel A., Agarwal R., Rudramurthy S.M., Shevkani M., Xess I., Sharma R., et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosisIndia. Emerg Infect Dis. 2021;27(9):2349–2359. doi: 10.3201/eid2709.210934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Walsch T.J., Gamaletsou M.N., McGinnis M.R., Hayden R.T., Kontoyiannis D.P. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S55–S60. doi: 10.1093/cid/cir868. [DOI] [PubMed] [Google Scholar]
  • 33.Harril W.C., Stewart M.G., Lee A.G., Cernoch P. Chronic rhinocerebral mucormycosis. Laryngoscope. 1996;106(10):1292–1297. doi: 10.1097/00005537-199610000-00024. [DOI] [PubMed] [Google Scholar]
  • 34.Sanghvi D., Kale H. Imaging of COVID-19-associated craniofacial mucormycosis: a black and white review of the "black fungus". Clin Radiol. 2021;76(11):812–819. doi: 10.1016/j.crad.2021.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Orguc S., Yücetürk A.V., Demir M.A., Goktan C. Rhinocerebral mucormycosis: perineural spread via the trigeminal nerve. J Clin Neurosci. 2005;12(4):484–486. doi: 10.1016/j.jocn.2004.07.015. [DOI] [PubMed] [Google Scholar]
  • 36.Frater J.L., Hall G.S., Procop G.W. Histologic features of zygomycosis: emphasis on perineural invasion and fungal pathology. Arch Pathol Lab Med. 2001;125(3):375–378. doi: 10.5858/2001-125-0375-HFOZ. [DOI] [PubMed] [Google Scholar]
  • 37.Pal P., Singh B., Singla S., Kaur R. Mucormycosis in COVID-19 pandemic and its neurovascular spread. Eur Arch Otorhinolaryngol. 2021:1–8. doi: 10.1007/s00405-021-07106-8. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D.P. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23–S34. doi: 10.1093/cid/cir866. [DOI] [PubMed] [Google Scholar]
  • 39.Chikley A., Ben-Ami R., Kontoyiannis D.P. Mucormycosis of the central nervous system. J Fungi. 2019;5:59. doi: 10.3390/jof5030059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wali U., Balkhair A., Al-Mujaini A. Cerebro-rhino-orbital mucormycosis: an update. J Infect Public Health. 2012;5(2):116–126. doi: 10.1016/j.jiph.2012.01.003. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Otolaryngology are provided here courtesy of Elsevier

RESOURCES